Dr Dominik Modest speaks to ecancer at ESMO 2019 in Barcelona about the VOLFI trial which compares a triplet chemotherapy with triplet chemotherapy plus the antibody panitumumab for colorectal cancer.

He outlines why this trial is important, having never established the specific role of this antibody before.

The primary endpoint was met, and there was a significant improvement between the arms.

Dr Modest rounds up by highlighting the importance of dosing, and some of the disparities still remaining around the treatment of this disease.